Professor Helmout Modjtahedi
Faculties, departments and locations
- Faculty of Health, Science, Social Care and Education
- Department of Biomolecular Sciences
- School of Life Sciences, Pharmacy and Chemistry
- Penrhyn Road
Professor of Cancer Biology
- Email:
- [email protected]
About
After receiving my degree in Medical Laboratory Science from the University of Ulster in 1989, I completed my PhD in Tumour Immunology at the Institute of Cancer Research / University of London in 1993.
Subsequently, I worked as a Postdoctoral Research Fellow at the Institute of Cancer Research / University of London (1993-1999) and was appointed to a Clinical Lectureship in Pharmaco-Immunology/Tumour Immunology at the European Institute of Health and Medical Sciences/Postgraduate Medical School at the University of Surrey (1999-2007).
I moved to the School of Life Sciences at Kingston University as Senior Lecturer in 2001 and became a Reader in 2007. In 2012, I was promoted to Professor of Cancer Biology. I currently teach a range of undergraduate and postgraduate bioscience programmes, with a particular focus on cancer-related subjects, and lead an active research group. In my laboratory, we particularly focus on cancer biology, therapeutics, and diagnostics.
Qualifications
- Certificate
- PhD, Tumour Immunology, Institute of Cancer Research, University of London
- First Class BSc Honours in Medical Laboratory Science, University of Ulster
Domains
My research expertise is translational cancer research. My research activities to date focus on four key areas:
- Studying the biological and clinical significance and targeting of growth factor receptors with tyrosine kinase activities in human cancers and other pathological conditions.
- Development of monoclonal antibody (mAb)-based products for use in cancer diagnosis and therapy.
- Predictive biomarkers for poor response to therapy with monoclonal antibodies and/or small molecule tyrosine kinase inhibitors in cancer.
- Discovery of overexpressed tumour antigens using monoclonal antibody-based technology.
Publications
Decoding drug resistance in cervical cancer cell lines: an AKT-independent mechanism
Bou Antoun, N., Grose, R., Modjtahedi, H., Walker, A. and Chioni, A., 2025, Molecular Oncology (19), S1pp 367-367, Published
The co-expression and cellular location of HER family members, EGFRvIII, putative cancer stem cell biomarkers CD44 and CD109 in patients with glioblastoma, and their impacts on prognosis
Mulliqi, Ermira, Khelwatty, Said, Bagwan, Izhar, Kamaludin, Ahmad, Morgan, Anna, Long, Natalie, Ashkan, Keyoumars and Modjtahedi, Helmout, 2025, Cancers (17), 7, Published
Development and characterization of three novel FGFR inhibitor resistant cervical cancer cell lines to help drive cervical cancer research
Bou Antoun, Nauf, Afshan Mahmood, Hiba Tun Noor, Walker, Anthony J., Modjtahedi, Helmout, Grose, Richard P. and Chioni, Athina Myrto, 2025, International Journal of Molecular Sciences (26), 5, Published
Expression of EGFRvIII and its co-expression with wild-type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma
Sherif, Ozlem, Khelwatty, Said A., Bagwan, Izhar, Seddon, Alan M., Dalgleish, Angus, Mudan, Satvinder and Modjtahedi, Helmout, 2024, Oncology Reports (52), 6, Published
The combination of afatinib with dasatinib or miransertib results in synergistic growth inhibition of stomach cancer cells
Al-Janaby, Tina, Nahi, Narmin, Seddon, Alan, Bagwan, Izhar, Khelwatty, Said and Modjtahedi, Helmout, 2024, World Journal of Oncology (15), 2pp 192-208, Published
The co-expression of HER family members and CD109 is common in pancreatic cancer
Khan, Tanzeel, Seddon, Alan, Khelwatty, Said, Dalgleish, Angus, Bagwan, Izhar, Mudan, Satvinder and Modjtahedi, Helmout, 2023, Medical Research Archives (11), 11, Published
Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors
Ismail, Mohamed A., Nasrallah, Gheyath K., Monne, Maria, AlSayab, Ali, Yassin, Mohamed A., Varadharaj, Govindarajulu, Younes, Salma, Sorio, Claudio, Cook, Richard, Modjtahedi, Helmout and Al-Dewik, Nader I., 2022, Gene (813), Published
Cytokine/chemokine release patterns and transcriptomic profiles of LPS/IFN╬│-activated human macrophages differentiated with heat-killed 'Mycobacterium obuense', M-CSF, or GM-CSF
Bazzi, Samer, El-Darzi, Emale, McDowell, Tina, Modjtahedi, Helmout, Mudan, Satvinder, Achkar, Marcel, Akle, Charles, Kadara, Humam and Bahr, Georges M., 2021, International Journal of Molecular Sciences (22), 13, Published
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Ismail, Mohamed A., Vezzalini, Marzia, Morsi, Hisham, Abujaber, Ahmad, Al Sayab, Ali, Siveen, Kodappully, Yassin, Mohamed A., Monne, Maria, Samara, Muthanna, Cook, Richard, Sorio, Claudio, Modjtahedi, Helmout and Al-Dewik, Nader I., 2021, Scientific Reports (11), Published
HER2 expression is predictive of survival in cetuximab treated patients with RAS wild type metastatic colorectal cancer
Khelwatty, Said A., Puvanenthiran, Soozana, Essapen, Sharadah, Bagwan, Izhar, Seddon, Alan M. and Modjtahedi, Helmout, 2021, Cancers (13), 4, Published
Therapeutic application of monoclonal antibodies in pancreatic cancer: advances, challenges and future opportunities
Arias‐pinilla, Gustavo A. and Modjtahedi, Helmout, 2021, Cancers (13), 8, Published
Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: implications for future clinical trials in pancreatic cancer
Khan, Tanzeel, Seddon, Alan M., Dalgleish, Angus G., Khelwatty, Said, Ioannou, Nikolaos, Mudan, Satvinder and Modjtahedi, Helmout, 2020, Oncology Reports (44), 6pp 2581-2594, Published
Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the state of Qatar
Ismail, Mohamed A., Samara, Muthanna, Al Sayab, Ali, Alsharshani, Mohamed, Yassin, Mohamed A., Varadharaj, Govindarajulu, Vezzalini, Marzia, Tomasello, Luisa, Monne, Maria, Morsi, Hisham, Qoronfleh, M. Walid, Zayed, Hatem, Cook, Richard, Sorio, Claudio, Modjtahedi, Helmout and Al-Dewik, Nader I., 2020, Molecular Genetics and Genomic Medicine (8), 10, Published
Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin ╬▒3 in human pancreatic cancer
Arias-Pinilla, Gustavo A., Dalgleish, Angus G., Mudan, Satvinder, Bagwan, Izhar, Walker, Anthony J. and Modjtahedi, Helmout, 2020, Scientific Reports (10), Published
Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan M. and Modjtahedi, Helmout, 2019, Oncotarget (10), 18pp 1704-1715, Published
Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer
Puvanenthiran, Soozana, Essapen, Sharadah, Haagsma, Ben, Bagwan, Izhar, Green, Margaret, Khelwatty, Said Abdullah, Seddon, Alan and Modjtahedi, Helmout, 2018, Oncotarget (9)pp 19662-19674, Published
Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer
Arias-Pinilla, Gustavo A., Dalgleish, Angus G., Mudan, Satvinder, Bagwan, Izhar, Walker, Anthony J. and Modjtahedi, Helmout, 2018, Oncotarget (9)pp 19994-20007, Published
Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody
Abdolahpour, Saeideh, Toliyat, Tayebeh, Omidfar, Kobra, Modjtahedi, Helmout, Wong, Albert J., Rasaee, Mohammad Javad, Kashanian, Susan and Paknejad, Maliheh, 2018, Artificial Cells, Nanomedicine and Biotechnology (46), 1pp 89-94, Published
A novel recombinant anti-epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model
Asadi-Ghalehni, Majid, Rasaee, Mohamad Javad, RajabiBazl, Masoumeh, Khosravani, Masood, Motaghinejad, Majid, Javanmardi, Masoud, Khalili, Saeed, Modjtahedi, Helmout and Sadroddiny, Esmaeil, 2017, Microbiology and Immunology (61), 12pp 531-538, Published
Immunomodulatory effects of heat killed 'Mycobacterium obuense' on human blood dendritic cells
Bazzi, Samer, Modjtahedi, Helmout, Mudan, Satvinder, Achkar, Marcel, Akle, Charles and Bahr, Georges M., 2017, Innate Immunity (23), 7pp 592-605, Published
Defining genome-wide expression and phenotypic contextual cues in macrophages generated by GM-CSF, M-CSF and heat-killed mycobacteria
Bazzi, Samer, El-Darzi, Emale, McDowell, Tina, Modjtahedi, Helmout, Mudan, Satvinder, Achkar, Marcel, Akle, Charles, Kadara, Humam and Bahr, Georges M., 2017, Frontiers in Immunology (8), Published
Inhibitory effects of culinary herbs and spices on the growth of HCA-7 colorectal cancer cells and their COX-2 expression
Jaksevicius, Andrius, Carew, Mark, Mistry, Calli, Modjtahedi, Helmout and Opara, Elizabeth I., 2017, Nutrients (9), 10, Published
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
Stanley, Aryan, Ashrafi, G. Hossein, Seddon, Alan M. and Modjtahedi, Helmout, 2017, Scientific Reports (7), 3964, Published
The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
Khelwatty, Said, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout, 2016, Oncotarget (8), 5pp 7666-7677, Published
Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of the HER inhibitors and cytotoxic drugs
Puvanenthiran, Soozana, Essapen, Sharadah, Seddon, Alan M. and Modjtahedi, Helmout, 2016, International Journal of Oncology (49), 5pp 1825-1838, Published
A preliminary characterisation of de novo lipogenesis in pancreatic (Capan-1) and liver (HepG2) cancer cell lines
Lambri, N., Snabaitis, A., Le Gresley, A., Modjtahedi, H. and Stolinski, M., 2016, European Journal of Cancer (61), S1pp S106, Published
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
Ioannou, Nikolaos, Seddon, Alan M., Dalgleish, Angus, Mackintosh, David, Solca, Flavio and Modjtahedi, Helmout, 2016, International Journal of Oncology (48), 3pp 908-918, Published
Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model
Bazzi, Samer, Modjtahedi, Helmout, Mudan, Satvinder, Akle, Charles and Bahr, Georges M., 2015, Immunobiology (220), 12pp 1293-1304, Published
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
Khelwatty, Said A., Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout, 2015, British Journal of Cancer (113), 7pp 1010-1019, Published
Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope
Navari, Mohsen, Zare, Mehrak, Javanmardi, Masoud, Asadi-Ghalehni, Majid, Modjtahedi, Helmout and Rasaee, Mohammad Javed, 2014, Immunopharmacology and Immunotoxicology (36), 5pp 309-315, E-pub ahead of print
Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.
Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan Michael and Modjtahedi, Helmout, 2014, PLoS ONE (9), 3, Published
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.
Modjtahedi, Helmout, Cho, Byoung Chul, Michel, Martin C. and Solca, Flavio, 2014, Naunyn-Schmiedeberg's Archives of Pharmacology, Published
GA201: a novel humanized and glycoengineered anti-EGFR antibody
Modjtahedi, Helmout and Eccles, Suzanne, 2014, Clinical Cancer Research (20), 4pp 1053-1054, Published
Resveratrol 3-O-d-glucuronide and resveratrol 4'-O-d-glucuronide inhibit colon cancer cell growth: Evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest
Polycarpou, Elena, Meira, Lisiane B., Carrington, Simon, Tyrrell, Elizabeth, Modjtahedi, Helmout and Carew, Mark A., 2013, Molecular Nutrition and Food Research (57), 10pp 1708-1717, Published
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
Ioannou, Nikolaos, Seddon, Alan M., Dalgleish, Angus, Mackintosh, David and Modjtahedi, Helmout, 2013, BMC Cancer (13), 41, Published
Prognostic significance and targeting of HER family in colorectal cancer
Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan Michael and Modjtahedi, Helmout, 2013, Frontiers in Bioscience (18), 2pp 394-421, Published
Co-targeting of HER family members and IGF-IR in pancreatic cancer
Modjtahedi, Helmout, Ioannou, Nikolaos, Dalgleish, Angus, Mackintosh, David and Seddon, Alan M., 2013, International Journal of Molecular Medicine (32), Published
Therapeutic application of monoclonal antibodies in cancer: advances and challenges
Modjtahedi, Helmout, Ali, Sumaira and Essapen, Sharadah, 2012, British Medical Bulletin (104), 1pp 41-59, Published
Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
Modjtahedi, H., Khelwatty, S. A., Kirk, R. S., Seddon, A. M., Essapen, S., Del Vecchio, C. A., Wong, A. J. and Eccles, S., 2012, British Journal of Cancer (106)pp 883-888, Published
Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer
Ioannou, Nikolaos, Seddon, Alan M., Dalgleish, Angus, MacKintosh, David and Modjtahedi, Helmout, 2012, Frontiers in Bioscience (17), 1pp 2698-2724, Published
Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
Ioannou, N., Dalgleish, A. G., Seddon, A. M., MacKintosh, D., Guertler, U., Solca, F. and Modjtahedi, H., 2011, British Journal of Cancer (105), 10pp 1554-1562, Published
Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members
Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan M. and Modjtahedi, Helmout, 2011, International Journal of Oncology (39), 2pp 483-491, Published
Periadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbit
Shafi, Shahida, Lamb, David, Modjtahedi, Helmout and Ferns, Gordon, 2010, International Journal of Experimental Pathology (91), 3pp 224-234, Published
Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
Modjtahedi, Helmout and Essapen, Sharadah, 2009, Anti-Cancer Drugs (20), 10pp 851-855, Published
Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells
Cunningham, Matthew P., Thomas, Hilary, Marks, Christopher, Green, Margaret, Fan, Zhen and Modjtahedi, Helmout, 2008, International Journal of Oncology (33), 5pp 1107-1113, Published
Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib
Cunningham, Matthew P., Thomas, Hilary, Fan, Zhen and Modjtahedi, Helmout, 2006, Cancer Research (66), 15pp 7708-7715, Published
Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer
Cunningham, Matthew P., Essapen, Sharadah, Thomas, Hilary, Green, Margaret, Lovell, David P., Topham, Clare, Marks, Christopher and Modjtahedi, Helmout, 2005, International Journal of Oncology (27), 2pp 317-325, Published
The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters.
Essapen, Sharadah, Thomas, Hilary, Green, Margaret, De Vries, Corrine, Cook, Martin G., Marks, Christopher, Topham, Clare and Modjtahedi, Helmout, 2004, International Journal of Oncology (24), 2pp 241-248, Published
Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti EGFR MAb ICR62: A two-pronged attack for tumour therapy.
Modjtahedi, Helmout, Moscatello, David K., Box, Gary, Green, Margaret, Shotton, Christine, Lamb, David J., Reynolds, Lesley J., Wong, Albert J., Dean, Christopher, Thomas, Hilary and Eccles, Suzanne, 2003, International Journal of Cancer (105), 2pp 273-280, Published
Decoding drug resistance in cervical cancer cell lines: an AKT-independent mechanism
Bou Antoun, N., Grose, R., Modjtahedi, H., Walker, A. and Chioni, A.(2025). [Published]
Development of two novel monoclonal antibodies against overexpressed antigens on pancreatic cancer cells for use in diagnosis and therapy
Arias Pinilla, GA, Dalgleish, AG, Mudan, S, Bagwan, I, Walker, AJ and Modjtahedi, H(2018). [Published]
Acquired resistance to anti-EGFR mAb ICR62 or afatinib is accompanied by upregulation of the EGFR in colorectal cancer
Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout(2013). [Published]